The FDA has granted De Novo clearance to a prescription treatment for irritable bowel syndrome (IBS) from Mahana Therapeutics. San Francisco-based Mahana Therapeutics’ Parallel uses cognitive-behavioral theory (CBT) to influence the communication between the brain and the gut to improve IBS, according to the company’s website. The device classification section of the FDA’s website confirms […]